Noninvasive Cardiac Mapping Vest Receives FDA Clearance


The electrode-covered vest can map the heart after capturing a single heartbeat.

(CardioInsight™ Mapping Vest. Image courtesy of Medtronic.)

First used commercially in the United States this week, a noninvasive mapping system by Medtronic has just received 510 (k) clearance from the US Food and Dug Administration (FDA).

The device, officially known as the CardioInsight Noninvasive 3D Mapping System, takes the form of an external vest that contains 252 electrode sensors that collect electrocardiogram signals in order to create 3D electroanatomic maps of the heart. As per a press release, by contouring to the torso the device “allows for continuous and simultaneous panoramic mapping of both atria or both ventricles, which cannot be achieved with current invasive methods.”

The rapidity of the mapping technology is noteworthy, claiming the ability to create a map after capturing a lone heartbeat. Cardiac mapping is an important diagnostic tool in understanding arrhythmias and their risks.

Vivek Reddy, MD, director of cardiac arrhythmia services at Mount Sinai Hospital, believes the technology represents both greater convenience in diagnosis and a potential cost-savings: “This system shifts mapping away from the EP lab, potentially saving time and enhancing the patient experience." Reddy, it should be noted, also receives financial consideration as a consultant for Medtronic.

CardioInsight was acquired by the company in 2015 and rolled into the Cardiac Rhythm and Heart Failure division of Medtronic AF Solutions.

The announcement of the FDA’s approval was made today in a press release from the company, which says it “will employ a strategic rollout of the technology in the geographies where it is cleared.”

Related Coverage:

First Balloon Expandable Stent Graft for Iliac Artery Gets FDA Approval

Cardiac Arrest: Time to Abandon Intubation?

Why Getting Patients to Take Cardiac Medications Is a Challenge

Related Videos
A panel of 5 cardiovascular experts
Video 5 - "Real-World Insights: Navigating Cardiac Myosin inhibitors in Practice" - Featuring 1 KOL
A panel of 5 cardiovascular experts
A panel of 5 cardiovascular experts
Video 4 - "Mavacamten in oHCM: Navigating the REMS Program for Safe, Optimal Outcomes "
Video 3 - "Aligning With 2023 ESC Guidelines in oHCM Treatment"
Robert Rosenson, MD | Credit: Cura Foundation
A panel of 5 cardiovascular experts
A panel of 5 cardiovascular experts
Robert Rosenson, MD | Credit: Cura Foundation
© 2024 MJH Life Sciences

All rights reserved.